United States Patent 8,252,809: Zolpidem Sublingual Formulation Scope, Claim Analysis, and Patent Landscape

US Patent 8,252,809 protects low-dose, rapidly dissolving zolpidem solid dosage forms designed for buccal or sublingual delivery in the treatment of middle-of-the-night insomnia, or MOTN insomnia. Its central commercial concept is a small zolpidem dose that produces a plasma concentration of approximately 25 to 50 ng/mL within 20 minutes, reaches at least 50% of Cmax within 10 minutes, and falls below 20 ng/mL four hours after dosing.

The strongest claim combination is a quick-dissolving tablet or lozenge containing approximately 1.75 mg or 3.5 mg of zolpidem hemitartrate, together with sodium carbonate and sodium bicarbonate, capable of raising saliva pH above 8.5 and delivering zolpidem through the oral mucosa.

What does US Patent 8,252,809 protect?

The patent protects a product defined by four principal elements:

A solid unit dosage composition.
Zolpidem or a zolpidem salt at a low dose.
Delivery through oral, buccal, or sublingual mucosa.
Pharmacokinetic performance appropriate for treating MOTN insomnia.

The claims are composition claims rather than pure method-of-treatment claims. A potentially infringing product must therefore satisfy the recited formulation and performance limitations, not merely contain zolpidem or be labeled for insomnia.

Core technical limitations

Limitation	Claim requirement
Active ingredient	Zolpidem or a salt thereof
Dosage form	Solid unit dosage composition
Administration route	Oral mucosa, including buccal or sublingual mucosa
Dose limitation	Less than 1.30 × 10^-5 moles of zolpidem in claim 1
Hemitartrate range	0.5 to 4.75 mg in claims 8 and 12
Target early exposure	Approximately 25 to 50 ng/mL within 20 minutes
Early Cmax requirement	At least 50% of maximum plasma concentration within 10 minutes
Four-hour exposure	Less than 20 ng/mL at four hours
Buffer option	Carbonate or bicarbonate salt
Narrow buffer system	Sodium carbonate plus sodium bicarbonate
Saliva pH	Greater than approximately 8.5
Dosage-form examples	Quick-dissolving tablet or lozenge
Dissolution	Dissolves in approximately two minutes or less, or at least 25% dissolves within five minutes
Commercial dose embodiments	Approximately 1.75 mg or 3.5 mg zolpidem hemitartrate

The claims combine formulation structure with in vivo pharmacokinetic results. That combination materially narrows the patent compared with a claim covering any sublingual zolpidem product.

How do independent claims 1 and 12 differ?

Claims 1 and 12 are the two principal independent claims.

Claim 1

Claim 1 requires:

a solid unit dosage composition;
zolpidem or a salt;
oral-mucosal delivery;
less than 1.30 × 10^-5 moles of zolpidem; and
a plasma concentration of approximately 25 to 50 ng/mL within 20 minutes.

The molar limitation is important. Zolpidem has a molecular weight of approximately 307.4 g/mol for the free base. The claimed upper limit corresponds to approximately 4.0 mg of zolpidem free base. The hemitartrate dose expressed in the dependent claims is a salt-weight convention and should not be treated as identical to the free-base mass.

Claim 12

Claim 12 uses a different dose formulation:

zolpidem or a salt;
at least one buffering agent;
oral-mucosal delivery;
0.5 to 4.75 mg of zolpidem hemitartrate; and
the same 25 to 50 ng/mL plasma concentration within 20 minutes.

Claim 12 is potentially broader in one respect because it requires only “at least one buffering agent,” rather than the carbonate/bicarbonate alternatives expressly recited in claims 4 and 21. It is narrower in another respect because it expressly requires the 0.5 to 4.75 mg hemitartrate range.

A formulation may fall within claim 1 without using the specific buffer system in claims 5 and 6. Conversely, a buffered formulation within the hemitartrate range may be evaluated under claim 12 even if it does not use sodium carbonate and sodium bicarbonate.

What is the scope of the buffer-system claims?

Claims 4 through 7 and claims 21 through 24 address alkalinization of saliva and rapid mucosal uptake.

The narrowest commercially relevant combination is:

zolpidem hemitartrate;
sodium carbonate;
sodium bicarbonate;
a quick-dissolving tablet or lozenge; and
delivery through buccal or sublingual tissue.

The pH limitation requires the binary buffer system to raise saliva above approximately pH 8.5, irrespective of the starting saliva pH. This is a functional limitation. The question is not only whether the formulation contains the two salts, but whether the system performs the specified pH function under the claim’s testing conditions.

Design-around implications

A competitor could attempt to avoid claims 5, 6, 22, and 23 by using:

a non-carbonate buffer;
a single buffering agent;
a different carbonate/bicarbonate ratio;
a formulation that does not raise saliva above pH 8.5; or
a dosage form that does not meet the rapid-dissolution limitations.

Those changes would not necessarily avoid claims 1 or 12. The competitor would still need to assess oral-mucosal delivery, dose, and pharmacokinetic performance.

The functional pH limitation may also create litigation issues concerning:

saliva composition;
starting saliva pH;
test population;
administration technique;
timing of pH measurement; and
whether “irrespective” requires performance across the full physiological range or only the range contemplated by the specification.

Which claims cover the 1.75 mg and 3.5 mg Intermezzo doses?

Claims 17, 18, 25, and 26 specifically recite approximately 1.75 mg and approximately 3.5 mg of zolpidem hemitartrate.

These claims target the two principal low-dose strengths associated with Intermezzo, the FDA-approved sublingual zolpidem product for adults who awaken during the night and have at least four hours remaining before planned awakening. The 3.5 mg strength was generally associated with men, while the 1.75 mg strength addressed women and other patients for whom lower exposure was appropriate under the product labeling.

The dose claims do not stand alone. They depend on earlier claim limitations. A product containing 1.75 mg or 3.5 mg is not automatically within the patent unless it also satisfies the applicable route, formulation, pharmacokinetic, buffering, or dissolution requirements inherited from the parent claim.

How should the pharmacokinetic limitations be analyzed?

The pharmacokinetic limitations are central to infringement and validity.

Early concentration requirement

Claims 1 and 12 require a plasma concentration of approximately 25 to 50 ng/mL within 20 minutes. This limitation distinguishes the claimed product from conventional swallowed zolpidem tablets, which are designed for bedtime administration and may have a different absorption profile.

The phrase “when evaluated in an appropriate patient population” creates an interpretive issue. The patent likely relies on clinical or pharmacokinetic testing in a defined insomnia population. A challenger could argue that the phrase lacks objective boundaries if the patent does not clearly identify:

the patient demographic;
fasting or fed state;
sampling schedule;
assay method;
dose administration conditions; and
statistical treatment of the concentration range.

Cmax and four-hour limitations

Claims 2, 3, 19, and 20 add:

at least 50% of Cmax within 10 minutes; and
less than 20 ng/mL at four hours.

These limitations seek to capture rapid onset with limited residual exposure. They may be useful against a formulation that matches the dose and route but produces slower absorption or prolonged exposure.

They also create proof burdens. A patent owner would generally need comparative pharmacokinetic evidence showing that the accused product meets each limitation under a legally relevant test protocol. Batch variation, patient variability, and differences in sampling times can affect the analysis.

What formulations are protected by US 8,252,809?

The claim set reaches several formulation categories.

Formulation category	Relevant claims	Scope
Generic solid oral-mucosal zolpidem form	1, 12	Broadest claimed categories
Low-dose zolpidem formulation	1, 8-10, 12, 17-18, 25-26	Dose and hemitartrate limitations
Carbonate or bicarbonate-buffered form	4, 21	Requires specified pH-adjusting agent
Sodium carbonate/sodium bicarbonate system	5-6, 22-23	Narrow binary buffer claims
Quick-dissolving tablet or lozenge	7, 24	Requires dosage-form limitation
Rapidly dissolving solid form	13-16	Two-minute or five-minute dissolution limitation
Sublingual or buccal form	11	Explicit mucosal-route limitation

The patent does not appear, from the supplied claims, to cover:

ordinary swallowed zolpidem tablets without oral-mucosal delivery;
extended-release zolpidem dosage forms;
non-solid liquid sprays unless they are legally captured by a broader claim construction;
products outside the claimed dose or pharmacokinetic ranges; or
zolpidem products used for conventional bedtime insomnia without the claimed formulation characteristics.

What is the FDA and Orange Book significance?

The FDA approved Intermezzo, zolpidem tartrate sublingual tablets, under NDA 021774 for treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. The product uses sublingual administration and low-dose strengths consistent with the commercial embodiments reflected in the claims. [2]

The Orange Book is the relevant FDA source for determining whether US Patent 8,252,809 was listed against the NDA, the listed use code, and the patent’s regulatory status. Patent listing, however, does not establish validity or infringement. A patent may be listed even when its claims are subject to Paragraph IV challenge, litigation, settlement, expiration, disclaimer, or delisting.

For an ANDA applicant, the key regulatory questions are:

Whether US 8,252,809 is listed against the reference product.
Whether the proposed generic contains the same sublingual dosage form.
Whether the ANDA makes a Paragraph IV certification.
Whether the applicant uses a section viii statement to omit a protected use.
Whether a 30-month stay or other litigation-related FDA restriction applies.

The active ingredient itself is not the principal barrier. Zolpidem is an established generic drug. The commercial barrier is the sublingual low-dose formulation, including its exposure profile and dissolution characteristics.

What Paragraph IV and litigation risks arise?

A Paragraph IV challenger would likely attack the patent on both validity and non-infringement grounds.

Potential validity arguments

The principal arguments would likely concern:

obviousness based on known zolpidem pharmacology and sublingual delivery;
written description support for the broad patient-population and pharmacokinetic language;
enablement across the full dose, buffer, dissolution, and performance ranges;
indefiniteness of “appropriate patient population”;
indefiniteness or lack of objective boundaries for “about,” “effective amount,” and “irrespective of the starting pH”; and
anticipation by earlier sublingual or buccal zolpidem disclosures.

Potential non-infringement arguments

A generic applicant could argue that its product:

does not deliver zolpidem across the oral mucosa;
uses a different salt or dose basis;
does not reach the specified concentration within 20 minutes;
does not reach 50% of Cmax within 10 minutes;
remains above 20 ng/mL at four hours, avoiding claims that require the lower level;
does not raise saliva above pH 8.5;
lacks sodium carbonate and sodium bicarbonate;
fails the dissolution limitations; or
does not meet the claimed hemitartrate range.

The independent claims are vulnerable to invalidity arguments because they combine multiple functional pharmacokinetic limitations with terminology that may require construction. They are also potentially difficult to design around if a product reproduces the same low-dose sublingual performance.

How strong is the patent estate for Intermezzo?

US 8,252,809 is strongest as a formulation-performance patent, not as a basic zolpidem patent.

Estate characteristic	Assessment
Active ingredient protection	Weak; zolpidem is off-patent as an active ingredient
Route protection	Meaningful; claims target buccal and sublingual delivery
Dose protection	Meaningful for low-dose hemitartrate products
Buffer protection	Strongest for sodium carbonate/sodium bicarbonate embodiments
PK protection	Commercially important but potentially difficult to prove
Dissolution protection	Useful against rapidly disintegrating copies
Method-of-use protection	Limited in the supplied claims; claims are compositions
Generic exposure	Concentrated in formulation design and ANDA certification
Biosimilar risk	Not applicable; zolpidem is a small molecule
Manufacturing barrier	Moderate; formulation replication and PK matching are the main issues

Patent strength depends on the surviving claims, prosecution history, terminal disclaimers, patent-term adjustment, Orange Book listing, and any litigation outcome. Those legal-status questions cannot be determined from the claim text alone.

How does US 8,252,809 compare with conventional zolpidem patents?

Conventional zolpidem products generally rely on immediate-release or extended-release oral dosage technologies. US 8,252,809 targets a different clinical and commercial problem: rapid treatment after a patient awakens during the night, with a low enough dose and exposure profile to reduce next-morning impairment.

The distinction is functional:

conventional oral zolpidem emphasizes bedtime administration;
the claimed product emphasizes late-night administration;
conventional products rely primarily on gastrointestinal absorption;
the claimed product relies on buccal or sublingual absorption; and
the claimed product uses lower doses and rapid early exposure.

This differentiation limits direct overlap with ordinary zolpidem tablets but increases the importance of formulation-specific patent claims.

What generic launch scenarios exist?

Three launch scenarios are commercially relevant.

At-risk launch

A generic company may launch after filing a Paragraph IV certification and before final resolution if it believes the patent is invalid, unenforceable, or not infringed. This creates exposure to patent litigation and possible damages or injunctive relief.

Carve-out launch

If the listed patent claims a method of use that can be omitted from the generic label, an ANDA applicant may use a section viii statement. The supplied claims are composition claims, so a carve-out may not eliminate all exposure if the generic product itself satisfies the formulation claims.

Post-expiration launch

The lowest-risk pathway is launch after expiration or a settlement date. The relevant date must be calculated from the patent’s term, any patent-term adjustment, terminal disclaimer, pediatric exclusivity, and litigation settlement provisions.

What licensing and settlement issues affect the landscape?

The supplied claim set does not identify a license, covenant not to sue, or settlement agreement. Any commercial analysis should distinguish:

ownership of US 8,252,809;
NDA sponsorship;
patent listing party;
marketing partner;
authorized generic arrangements; and
litigation settlement rights.

A settlement may permit an ANDA launch before patent expiration without invalidating the patent. It may also impose restrictions on launch timing, dosage strengths, authorized distribution, or manufacturing source.

Key Takeaways

US 8,252,809 targets low-dose, solid oral-mucosal zolpidem products for MOTN insomnia.
Claims 1 and 12 are the principal independent claims.
The patent combines structural formulation limitations with pharmacokinetic performance requirements.
The most commercially important embodiments are approximately 1.75 mg and 3.5 mg zolpidem hemitartrate.
Sodium carbonate and sodium bicarbonate form the narrowest and most formulation-specific buffer combination.
The patent does not cover ordinary swallowed zolpidem products merely because they contain zolpidem.
The main generic risks are formulation overlap, oral-mucosal delivery, rapid dissolution, and pharmacokinetic matching.
Zolpidem’s active-ingredient exclusivity is distinct from the formulation protection claimed by this patent.
Biosimilar analysis is inapplicable because zolpidem is a small-molecule drug.
Patent expiration, Orange Book listing, Paragraph IV activity, ownership, and settlement status require review of the current USPTO, FDA, and litigation records.

FAQs

Does US 8,252,809 cover all sublingual zolpidem products?

No. The product must satisfy the applicable dose, pharmacokinetic, formulation, delivery, and, for narrower claims, buffer or dissolution limitations.

Can a generic avoid the patent by using zolpidem tartrate instead of zolpidem hemitartrate?

Possibly, but salt substitution alone may not avoid the broader claims. Claims 1 and some dependent claims refer to zolpidem or a salt thereof, while other claims expressly recite zolpidem hemitartrate.

Is Intermezzo protected by a biologic exclusivity framework?

No. Intermezzo contains zolpidem, a small-molecule active ingredient, and is regulated through the NDA/ANDA framework rather than the biosimilar pathway.

Does a rapid-dissolving tablet automatically infringe the dissolution claims?

No. It must also satisfy the inherited limitations, including zolpidem content, oral-mucosal delivery, and the applicable pharmacokinetic requirements.

Are the claims limited to treatment of women with insomnia?

No. The claims refer to an appropriate patient population and do not expressly limit the composition to women. The commercial labeling and clinical rationale for the 1.75 mg strength are separate from the literal claim scope.

References

United States Patent and Trademark Office. (2012). United States Patent No. 8,252,809, solid unit dosage compositions for treatment of middle-of-the-night insomnia.
U.S. Food and Drug Administration. (2011). Intermezzo prescribing information: Zolpidem tartrate sublingual tablets.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Amendments and requests for final approval to paragraph IV certification.
21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006249761	⤷ Start Trial
Brazil	PI0609984	⤷ Start Trial
Canada	2609330	⤷ Start Trial
China	101198327	⤷ Start Trial
European Patent Office	1883408	⤷ Start Trial
Hong Kong	1118203	⤷ Start Trial
Japan	2008542299	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,252,809

Summary for Patent: 8,252,809